Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers Symposium could shift second-line approaches in metastatic renal cell carcinoma.
Rahul A. Parikh, MD
Articles by Rahul A. Parikh, MD
Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy.
Bone-protecting therapies are an important part of delivering optimal care in patients with prostate cancer who are treated with androgen-deprivation therapy.
The rationale for KEYNOTE-B15 is to determine whether perioperative enfortumab Bedouin (Padcev) and pembrolizumab (Keytruda) can improve outcomes in patients with muscle-invasive bladder cancer compared with standard of care.